<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="int-interactant" /><meta name="keywords" content="" /><title>Phenobarbital: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="41001i437.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="41001i437.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=41001i437.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="41001.htm">Appendix 1 Interactions</a> &gt; <a href="53178.htm">List of drug interactions</a> &gt; <a href="41001i276.htm">Antiepileptics</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="41001i1195.htm" title="Previous: Retigabine">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="41001i1003.htm" title="Next: Primidone">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_41001i437">Phenobarbital</h1><div id="pC" class="jN"><p class="int-specific-drug-name"><b>Phenobarbital</b>
          has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody><tr><td><a href="41001i907.htm" name="_907">Abacavir</a></td><td> phenobarbital possibly reduces plasma concentration of abacavir </td><td></td></tr><tr><td><a href="41001i20.htm">Alcohol</a></td><td>increased sedative effect when  phenobarbital given with alcohol </td><td></td></tr><tr><td><a href="41001i241.htm" name="_241">Antidepressants, Tricyclic</a></td><td class="cBV"><b> phenobarbital possibly accelerates metabolism of tricyclics (reduced plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i1010.htm" name="_1010">Aprepitant</a></td><td> phenobarbital possibly reduces plasma concentration of aprepitant </td><td></td></tr><tr><td><a href="41001i1011.htm" name="_1011">Aripiprazole</a></td><td class="cBV"><b> phenobarbital possibly reduces plasma concentration of aripiprazole—increase dose of aripiprazole</b></td><td></td></tr><tr><td><a href="41001i1214.htm" name="_1214">Boceprevir</a></td><td class="cBV"><b>avoidance of  phenobarbital advised by manufacturer of boceprevir (plasma concentration of boceprevir possibly reduced)</b></td><td></td></tr><tr><td><a href="41001i1204.htm" name="_1204">Cabazitaxel</a></td><td class="cBV"><b>avoidance of  phenobarbital advised by manufacturer of cabazitaxel </b></td><td></td></tr><tr><td><a href="41001i466.htm" name="_466">Calcium-channel Blockers</a></td><td class="cBV"><b> phenobarbital probably reduces effects of calcium-channel blockers </b></td><td>Dihydropyridine calcium-channel blockers include amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and nimodipine</td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td>plasma concentration of  phenobarbital possibly increased by carbamazepine </td><td></td></tr><tr><td><a href="41001i550.htm">Carbonic Anhydrase Inhibitors</a></td><td>increased risk of osteomalacia when  phenobarbital given with carbonic anhydrase inhibitors </td><td></td></tr><tr><td><a href="41001i158.htm" name="_158">Chloramphenicol</a></td><td class="cBV"><b> phenobarbital possibly accelerates metabolism of chloramphenicol (reduced plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i374.htm">Chlorpromazine</a></td><td>plasma concentration of both drugs reduced when  phenobarbital given with chlorpromazine </td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b> phenobarbital accelerates metabolism of ciclosporin (reduced plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i408.htm" name="_408">Clonazepam</a></td><td> phenobarbital often reduces plasma concentration of clonazepam </td><td></td></tr><tr><td><a href="41001i364.htm" name="_364">Clozapine</a></td><td> phenobarbital possibly reduces plasma concentration of clozapine </td><td>Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</td></tr><tr><td><a href="41001i484.htm" name="_484">Corticosteroids</a></td><td class="cBV"><b> phenobarbital accelerates metabolism of corticosteroids (reduced effect)</b></td><td>Interactions do not generally apply to corticosteroids used for topical action (including inhalation) unless specified</td></tr><tr><td><a href="41001i220.htm" name="_220">Coumarins</a></td><td class="cBV"><b> phenobarbital accelerates metabolism of coumarins (reduced anticoagulant effect)</b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i1091.htm" name="_1091">Darunavir</a></td><td> phenobarbital possibly reduces plasma concentration of darunavir </td><td></td></tr><tr><td><a href="41001i119.htm">Disopyramide</a></td><td> phenobarbital accelerates metabolism of disopyramide (reduced plasma concentration)</td><td></td></tr><tr><td><a href="41001i212.htm">Doxycycline</a></td><td> phenobarbital accelerates metabolism of doxycycline (reduced plasma concentration)</td><td></td></tr><tr><td><a href="41001i1176.htm" name="_1176">Dronedarone</a></td><td class="cBV"><b> phenobarbital possibly reduces plasma concentration of dronedarone—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1025.htm" name="_1025">Eplerenone</a></td><td class="cBV"><b> phenobarbital reduces plasma concentration of eplerenone—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i281.htm" name="_281">Ethosuximide</a></td><td> phenobarbital possibly reduces plasma concentration of ethosuximide </td><td></td></tr><tr><td><a href="41001i1031.htm" name="_1031">Etoposide</a></td><td> phenobarbital possibly reduces plasma concentration of etoposide </td><td></td></tr><tr><td><a href="41001i1135.htm" name="_1135">Etravirine</a></td><td>avoidance of  phenobarbital advised by manufacturer of etravirine </td><td></td></tr><tr><td><a href="41001i860.htm">Folates</a></td><td>plasma concentration of  phenobarbital possibly reduced by folates </td><td></td></tr><tr><td><a href="41001i1019.htm" name="_1019">Fosamprenavir</a></td><td> phenobarbital possibly reduces plasma concentration of fosamprenavir </td><td>Fosamprenavir is a prodrug of amprenavir</td></tr><tr><td><a href="41001i1170.htm" name="_1170">Gefitinib</a></td><td>avoidance of  phenobarbital advised by manufacturer of gefitinib </td><td></td></tr><tr><td><a href="41001i291.htm">Griseofulvin</a></td><td> phenobarbital reduces absorption of griseofulvin (reduced effect)</td><td></td></tr><tr><td><a href="41001i387.htm">Haloperidol</a></td><td> phenobarbital accelerates metabolism of haloperidol (reduced plasma concentration)</td><td></td></tr><tr><td><a href="41001i398.htm" name="_398">Indinavir</a></td><td class="cBV"><b> phenobarbital possibly reduces plasma concentration of indinavir </b></td><td></td></tr><tr><td><a href="41001i1006.htm" name="_1006">Irinotecan</a></td><td> phenobarbital reduces plasma concentration of irinotecan and its active metabolite</td><td></td></tr><tr><td><a href="41001i472.htm" name="_472">Isradipine</a></td><td>avoidance of  phenobarbital advised by manufacturer of isradipine </td><td></td></tr><tr><td><a href="41001i302.htm" name="_302">Itraconazole</a></td><td> phenobarbital possibly reduces plasma concentration of itraconazole </td><td></td></tr><tr><td><a href="41001i283.htm" name="_283">Lamotrigine</a></td><td> phenobarbital reduces plasma concentration of lamotrigine </td><td></td></tr><tr><td><a href="41001i922.htm" name="_922">Lopinavir</a></td><td class="cBV"><b> phenobarbital possibly reduces plasma concentration of lopinavir </b></td><td>In combination with ritonavir as <i>Kaletra</i>® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</td></tr><tr><td><a href="41001i97.htm" name="_97">Methadone</a></td><td> phenobarbital reduces plasma concentration of methadone </td><td></td></tr><tr><td><a href="41001i718.htm">Methylphenidate</a></td><td>plasma concentration of  phenobarbital possibly increased by methylphenidate </td><td></td></tr><tr><td><a href="41001i170.htm" name="_170">Metronidazole</a></td><td> phenobarbital accelerates metabolism of metronidazole (reduced effect)</td><td>Interactions do not apply to topical metronidazole preparations </td></tr><tr><td><a href="41001i254.htm">Mianserin</a></td><td class="cBV"><b> phenobarbital accelerates metabolism of mianserin (reduced plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i845.htm" name="_845">Montelukast</a></td><td> phenobarbital reduces plasma concentration of montelukast </td><td></td></tr><tr><td><a href="41001i842.htm" name="_842">Nelfinavir</a></td><td class="cBV"><b> phenobarbital possibly reduces plasma concentration of nelfinavir </b></td><td></td></tr><tr><td><a href="41001i476.htm" name="_476">Nimodipine</a></td><td class="cBV"><b>avoidance of  phenobarbital advised by manufacturer of nimodipine (plasma concentration of nimodipine reduced)</b></td><td></td></tr><tr><td><a href="41001i636.htm" name="_636">Oestrogens</a></td><td class="cBV"><b> phenobarbital accelerates metabolism of oestrogens (reduced contraceptive effect—see <a title="target-block: COCs interactions" href="4552.htm#_120026">section 7.3.1</a>)</b></td><td>Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="4552.htm#_120026">section 7.3.1</a></td></tr><tr><td><a href="41001i900.htm" name="_900">Oxcarbazepine</a></td><td>plasma concentration of  phenobarbital increased by oxcarbazepine , also plasma concentration of an active metabolite of oxcarbazepine reduced</td><td></td></tr><tr><td><a href="41001i59.htm" name="_59">Paracetamol</a></td><td> phenobarbital possibly accelerates metabolism of paracetamol (also isolated reports of hepatotoxicity)</td><td></td></tr><tr><td><a href="41001i236.htm" name="_236">Paroxetine</a></td><td> phenobarbital reduces plasma concentration of paroxetine </td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td>plasma concentration of  phenobarbital often increased by phenytoin , plasma concentration of phenytoin often reduced but may be increased</td><td></td></tr><tr><td><a href="41001i1060.htm" name="_1060">Posaconazole</a></td><td class="cBV"><b> phenobarbital possibly reduces plasma concentration of posaconazole </b></td><td></td></tr><tr><td><a href="41001i664.htm" name="_664">Progestogens</a></td><td class="cBV"><b> phenobarbital accelerates metabolism of progestogens (reduced contraceptive effect—see <a title="target-block: COCs interactions" href="4552.htm#_120026">section 7.3.1</a>)</b></td><td>Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="" href="4552.htm#_120026">section 7.3.1</a>. For further information on interactions of oral progestogen-only contraceptives, see also <a title="" href="4572.htm#_4572.2">section 7.3.2.1</a>; parenteral progestogen-only contraceptives, see also <a title="" href="4580.htm#_4580.4">section 7.3.2.2</a>; the intra-uterine progestogen-only device, see also <a title="" href="31947.htm#_31947.1">section 7.3.2.3</a>; hormonal emergency contraception, see also <a title="" href="130057.htm#_100043.3">section 7.3.5</a></td></tr><tr><td><a href="41001i793.htm" name="_793">Propranolol</a></td><td> phenobarbital possibly reduces plasma concentration of propranolol </td><td></td></tr><tr><td><a href="41001i231.htm" name="_231">Reboxetine</a></td><td> phenobarbital possibly reduces plasma concentration of reboxetine </td><td></td></tr><tr><td><a href="41001i201.htm" name="_201">Rifampicin</a></td><td> phenobarbital possibly reduces plasma concentration of rifampicin </td><td></td></tr><tr><td><a href="41001i1102.htm" name="_1102">Rufinamide</a></td><td> phenobarbital possibly reduces plasma concentration of rufinamide </td><td></td></tr><tr><td><a href="41001i791.htm" name="_791">Saquinavir</a></td><td class="cBV"><b> phenobarbital possibly reduces plasma concentration of saquinavir </b></td><td></td></tr><tr><td><a href="41001i1067.htm" name="_1067">Sodium Oxybate</a></td><td>avoidance of  phenobarbital advised by manufacturer of sodium oxybate </td><td></td></tr><tr><td><a href="41001i1144.htm">Stiripentol</a></td><td class="cBV"><b>plasma concentration of  phenobarbital increased by stiripentol </b></td><td></td></tr><tr><td><a href="41001i730.htm" name="_730">Tacrolimus</a></td><td class="cBV"><b> phenobarbital reduces plasma concentration of tacrolimus </b></td><td>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</td></tr><tr><td><a href="41001i1216.htm" name="_1216">Telaprevir</a></td><td class="cBV"><b>avoidance of  phenobarbital advised by manufacturer of telaprevir </b></td><td></td></tr><tr><td><a href="41001i946.htm">Telithromycin</a></td><td class="cBV"><b> phenobarbital reduces plasma concentration of telithromycin (avoid during and for 2 weeks after phenobarbital)</b></td><td></td></tr><tr><td><a href="41001i734.htm" name="_734">Theophylline</a></td><td class="cBV"><b> phenobarbital accelerates metabolism of theophylline (reduced effect)</b></td><td></td></tr><tr><td><a href="41001i935.htm" name="_935">Thyroid Hormones</a></td><td> phenobarbital accelerates metabolism of thyroid hormones (may increase requirements for thyroid hormones in hypothyroidism)</td><td></td></tr><tr><td><a href="41001i857.htm" name="_857">Tiagabine</a></td><td> phenobarbital reduces plasma concentration of tiagabine </td><td></td></tr><tr><td><a href="41001i1203.htm" name="_1203">Ticagrelor</a></td><td> phenobarbital possibly reduces plasma concentration of ticagrelor </td><td></td></tr><tr><td><a href="41001i285.htm" name="_285">Topiramate</a></td><td> phenobarbital possibly reduces plasma concentration of topiramate </td><td></td></tr><tr><td><a href="41001i582.htm">Toremifene</a></td><td> phenobarbital accelerates metabolism of toremifene (reduced plasma concentration)</td><td></td></tr><tr><td><a href="41001i1163.htm" name="_1163">Ulipristal</a></td><td class="cBV"><b>avoidance of  phenobarbital advised by manufacturer of ulipristal (contraceptive effect of ulipristal possibly reduced)</b></td><td></td></tr><tr><td><a href="41001i286.htm">Valproate</a></td><td>plasma concentration of  phenobarbital increased by valproate (also plasma concentration of valproate reduced)</td><td></td></tr><tr><td><a href="41001i768.htm" name="_768">Vitamin D</a></td><td> phenobarbital possibly increases requirements for vitamin D </td><td></td></tr><tr><td><a href="41001i948.htm" name="_948">Voriconazole</a></td><td class="cBV"><b> phenobarbital possibly reduces plasma concentration of voriconazole—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1040.htm" name="_1040">Zonisamide</a></td><td> phenobarbital reduces plasma concentration of zonisamide </td><td></td></tr></tbody></table><p>Phenobarbital belongs to <b>Antiepileptics</b>
          and will have the following interactions:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>









<tr><td><a href="41001i232.htm">Antidepressants, SSRI</a></td><td class="cBV"><b>anticonvulsant effect of  antiepileptics antagonised by SSRIs (convulsive threshold lowered)</b></td><td></td></tr><tr><td><a href="41001i241.htm">Antidepressants, Tricyclic</a></td><td class="cBV"><b>anticonvulsant effect of  antiepileptics antagonised by tricyclics (convulsive threshold lowered)</b></td><td></td></tr><tr><td><a href="41001i252.htm">Antidepressants, Tricyclic (related)</a></td><td class="cBV"><b>anticonvulsant effect of  antiepileptics possibly antagonised by tricyclic-related antidepressants (convulsive threshold lowered)</b></td><td></td></tr><tr><td><a href="41001i363.htm">Antipsychotics</a></td><td class="cBV"><b>anticonvulsant effect of  antiepileptics antagonised by antipsychotics (convulsive threshold lowered)</b></td><td>Increased risk of toxicity with myelosuppressive drugs</td></tr><tr><td><a href="41001i335.htm">Chloroquine and Hydroxychloroquine</a></td><td>possible increased risk of convulsions when  antiepileptics given with chloroquine and hydroxychloroquine </td><td></td></tr><tr><td><a href="41001i257.htm">MAOIs</a></td><td>anticonvulsant effect of  antiepileptics possibly antagonised by MAOIs (convulsive threshold lowered)</td><td>For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</td></tr><tr><td><a href="41001i337.htm">Mefloquine</a></td><td class="cBV"><b>anticonvulsant effect of  antiepileptics antagonised by mefloquine </b></td><td></td></tr><tr><td><a href="41001i856.htm">Orlistat</a></td><td class="cBV"><b>possible increased risk of convulsions when  antiepileptics given with orlistat </b></td><td></td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td class="cBV"><b>avoid concomitant use of  antiepileptics with St John's wort </b></td><td></td></tr></tbody></table><p><b>Primidone</b> belongs to
      <b>Phenobarbital</b>
          but has no specific interaction information.
        </p><div>Primidone interactions as for phenobarbital</div></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="41001i1003.htm" title="Primidone">Primidone</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="41001i1195.htm">Previous: Retigabine</a> | <a class="top" href="41001i437.htm#">Top</a> | <a accesskey="]" href="41001i1003.htm">Next: Primidone</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>